These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7104231)

  • 41. [Monitoring for oral anticoagulant therapy].
    Nakagawa K; Nakahara Y; Tsuji H
    Rinsho Ketsueki; 1995 Apr; 36(4):308-13. PubMed ID: 7783335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Determination of thromboplastin time with a new standardized thromboplastin from human placenta: results of a cooperative study].
    Barthels M; Bruhn HD; Duckert F; Meyer JG; Dati F; Fuhge P
    J Clin Chem Clin Biochem; 1987 Apr; 25(4):267-80. PubMed ID: 3625130
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of a standard and a sensitive thromboplastin in monitoring low intensity oral anticoagulant therapy.
    Brophy MT; Fiore LD; Lau J; Goodwin R; Lopez A; Deykin D
    Am J Clin Pathol; 1994 Jul; 102(1):134-7. PubMed ID: 8037160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monitoring warfarin therapy in patients with lupus anticoagulants.
    Moll S; Ortel TL
    Ann Intern Med; 1997 Aug; 127(3):177-85. PubMed ID: 9245222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Imprecision of prothrombin time monitoring of oral anticoagulation. A survey of hospital laboratories.
    Ansell JE
    Am J Clin Pathol; 1992 Aug; 98(2):237-9. PubMed ID: 1510036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Control of oral anticoagulant therapy using the Hepato-Quick-test].
    Heene DL
    Med Welt; 1974 Sep; 25(39):1529-31. PubMed ID: 4214975
    [No Abstract]   [Full Text] [Related]  

  • 47. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
    Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
    J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reaction to long-term oral anticoagulant therapy. A comparison of prothrombin and partial thromboplastin tests.
    Eastham RD
    J Clin Pathol; 1970 Dec; 23(9):827. PubMed ID: 5504384
    [No Abstract]   [Full Text] [Related]  

  • 49. [Evaluation of prothrombin time and thrombotest and hepaplastin test for the control of oral anticoagulant therapy].
    Murakami S; Muratani H; Kikuchi T; Fujimoto S; Hayashi T; Inai S; Imaoka S
    Rinsho Byori; 1983 Feb; 31(2):210-4. PubMed ID: 6855001
    [No Abstract]   [Full Text] [Related]  

  • 50. Long-term patient self-management of oral anticoagulation.
    Ansell JE; Patel N; Ostrovsky D; Nozzolillo E; Peterson AM; Fish L
    Arch Intern Med; 1995 Nov; 155(20):2185-9. PubMed ID: 7487240
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of provision of time in therapeutic range value on anticoagulation management in atrial fibrillation patients on warfarin.
    Huang D; Wong CL; Cheng KW; Chan PH; Yue WS; Wong CK; Ho CW; Wong ICK; Chan EW; Siu CW
    Postgrad Med J; 2018 Apr; 94(1110):207-211. PubMed ID: 29459408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk.
    Larson BJ; Zumberg MS; Kitchens CS
    Chest; 2005 Mar; 127(3):922-7. PubMed ID: 15764777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting the dose of warfarin for therapeutic anticoagulation.
    Sharma NK; Routledge PA; Rawlins MD; Davies DM
    Thromb Haemost; 1982 Jun; 47(3):230-1. PubMed ID: 7112495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Control of oral anticoagulant treatment by chromogenic prothrombin assay.
    O'Donnell JR; Walker ID; Davidson JF
    J Clin Pathol; 1987 May; 40(5):500-4. PubMed ID: 3108332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The British system for anticoagulant control.
    Poller L
    Thromb Diath Haemorrh; 1975 Apr; 33(2):157-62. PubMed ID: 1138413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An assessment of an amidolytic assay for factor VII in the laboratory control of oral anticoagulants.
    Poller L; Thomson JM; Bodzenta A; Easton AC; Latallo ZS; Chmielewska J
    Br J Haematol; 1981 Sep; 49(1):69-75. PubMed ID: 7272230
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals].
    Benavides F; Grossman N; Poggi H; Nieto E; Bertrán A; Araos D; Vásquez M; Ibarra I; Cáceres F; Espinoza K; Lagos M; Repetto M G
    Rev Med Chil; 2015 Nov; 143(11):1369-76. PubMed ID: 26757860
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The "therapeutic range" of the one-stage prothrombin time in the control of anticoagulant therapy: the effect of different thromboplastin preparations.
    Bailey EL; Harper TA; Pinkerton PH
    Can Med Assoc J; 1971 Nov; 105(10):1041-3 passim. PubMed ID: 5150206
    [TBL] [Abstract][Full Text] [Related]  

  • 59. "Therapeutic range" for oral anticoagulant therapy.
    Hirsh J; Deykin D; Poller L
    Chest; 1986 Feb; 89(2 Suppl):11S-15S. PubMed ID: 3510825
    [No Abstract]   [Full Text] [Related]  

  • 60. Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK).
    Cosmi B; Palareti G; Carpanedo M; Pengo V; Biasiolo A; Rampazzo P; Morstabilini G; Testa S
    Haematologica; 2000 Aug; 85(8):826-31. PubMed ID: 10942929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.